03/12/2018 | Press release | Distributed by Public on 03/13/2018 09:28
Biologic drug products are not new - their development began decades ago; the first monoclonal antibody was commercialized in 1986.  With the increasing availability of genetic information, and better understanding of subcellular cascades and disease processes, the number of biologic drug products available has increased substantially in response to an exponential growth in targets. 
Biologic drug products can be composed of sugars, proteins, nucleic acids or combinations thereof - also they may be composed of living entities such as cells and tissues. Frequently, they involve large, complex molecules  and are often administered parenterally .
A critical concern in formulation development is the relationship between API concentration and drug product viscosity. Large molecules result in high viscosities, but high viscosity drug products cannot be injected easily. As a result, dilution is performed, which may result in large dosage volumes.
Delivery of large volumes is a challenge. A way to address this is with pre-programmable, easy-to-use, wearable injectors - such as the West SmartDose® drug delivery platform - that can deliver larger volumes at a pre-programmed delivery time. West is committed to safe, efficient delivery of drug products to patients.